Fig. 2.

Etomoxir inhibits whole-body FAO. Kinetics of the appearance of ³H-palmitate (A) and ¹⁴C-2-bromopalmitate (B) in the blood. C: Determination of appearance of the β-oxidation by-product ³H₂O in the blood (aqueous phase) of 2 h fasted male C57Bl/6J mice pretreated with either saline (black circles) or the CPT1-inhibitor etomoxir (white squares). D: Plasma FFA levels were measured at the time of pretreatment (t = −15), the beginning of the tracer infusion (t = 0), and 12 min after the infusion onset (t = 12). E: Rate of whole-body FAO. F: Tissue-specific uptake of non-β-oxidizable ¹⁴C-2-bromopalmitate of saline- or etomoxir-treated mice. Filled bars, saline; open bars, etomoxir. Results are shown as mean ± SEM. * P < 0.05. n = 7 mice. DPM, disintegrations per minute; Sol, soleus.